Vivos’ Oral Appliances Receive Full Approval for Medicare Reimbursement
The company’s CARE oral devices for sleep apnea are now eligible for Medicare reimbursement, broadening accessible treatment alternatives for beneficiaries.
The company’s CARE oral devices for sleep apnea are now eligible for Medicare reimbursement, broadening accessible treatment alternatives for beneficiaries.
Vivos receives the FDA's first clearance for oral appliances to treat severe OSA, while ProSomnus accelerates its regulatory submission for a severe indication. A look at how these devices work, their efficacy, and what it means for patient care.
Vivos highlighted certain market developments that it says are creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies.
Read MoreThe FDA is in the process of reviewing the company’s premarket notification for its ProSomnus EVO oral device for the treatment of patients with severe obstructive sleep apnea.
Read MoreOral appliance therapy maker ProSomnus Inc announced its capability to support sleep apnea patients and sleep physicians affected by the discontinuation of certain CPAP devices.
Read MoreThe device uses a molding method of being place in hot water to create a customizable fit for the user.
Read MoreVivos announced it is seeing positive preliminary metrics after receiving FDA clearance for its CARE oral appliances to treat severe OSA.
Read MoreUnitedHealthcare’s updated medical policy for obstructive and central sleep apnea establishes oral appliance therapy as a prerequisite therapy for surgical treatment in adult patients with moderate to severe OSA.
Read MoreA Tennessee dentist who has been sued by multiple TMJ and sleep apnea patients over an unproven dental device he invented has said under oath that he never taught dentists to use the device for those ailments—contradicting video footage of him telling dentists how to use it.
Read MoreA recent study reveals that precision oral appliance therapy devices, developed by ProSomnus Inc, are effective in treating patients with obstructive sleep apnea.
Read MoreThe acquisition aims to improve the landscape of dental sleep medicine by addressing a long-standing challenge in the industry: medical billing.
Read MoreA clinical trial demonstrating the efficacy of an EPAP accessory used with an oral appliance for the treatment of obstructive sleep apnea was awarded the CHEST 2023 Top Abstract Poster Award.
Read MoreVivos Therapeutics reported a decrease in revenue for the third quarter, juxtaposed against its efforts to expand internationally and form strategic partnerships in the sleep treatment market.
Read MoreProSomnus Inc, a manufacturer of oral appliance therapy, reported record third-quarter revenue, marking its seventh consecutive quarter of revenue growth.
Read MoreVivos Therapeutics signed a US nationwide agreement with Lincare, a supplier of in-home respiratory therapy products and services, for the distribution of Vivos’ oral appliances.
Read MoreVivos Therapeutics’ flagship daytime-nighttime appliance (DNA) will be tested against CPAP in a clinical trial at Stanford Medicine.
Read MoreVivos Therapeutics Inc signed an exclusive distribution agreement to bolster its international expansion across the Middle East-North Africa region.
Read More